EZH2-mediated H3K27 trimethylation mediates neurodegeneration in ataxia-telangiectasia.
Jiali LiRonald P HartElyse M MallimoMavis R SwerdelAlexander W KusnecovKarl HerrupPublished in: Nature neuroscience (2013)
The symptoms of ataxia-telangiectasia (A-T) include a progressive neurodegeneration caused by ATM protein deficiency. We previously found that nuclear accumulation of histone deacetylase-4, HDAC4, contributes to this degeneration; we now report that increased trimethylation of histone H3 on Lys27 (H3K27me3) mediated by polycomb repressive complex 2 (PRC2) is also important in the A-T phenotype. Enhancer of zeste homolog 2 (EZH2), a core catalytic component of PRC2, is a new ATM kinase target, and ATM-mediated phosphorylation of EZH2 on Ser734 reduces protein stability. Thus, PRC2 formation is elevated along with H3K27me3 in ATM deficiency. Chromatin immunoprecipitation and sequencing showed an increase in H3K27me3 'marks' and a dramatic shift in their location. The change of H3K27me3 chromatin-binding pattern is directly related to cell cycle reentry and cell death of ATM-deficient neurons. Lentiviral knockdown of EZH2 rescued Purkinje cell degeneration and behavioral abnormalities in Atm(-/-) mice, demonstrating that EZH2 hyperactivity is another key factor in A-T neurodegeneration.
Keyphrases
- dna damage
- dna repair
- dna damage response
- cell cycle
- histone deacetylase
- long noncoding rna
- long non coding rna
- cell death
- oxidative stress
- binding protein
- gene expression
- transcription factor
- single cell
- cell proliferation
- early onset
- multiple sclerosis
- genome wide
- stem cells
- spinal cord
- protein kinase
- adipose tissue
- protein protein
- type diabetes
- dna methylation
- tyrosine kinase
- spinal cord injury
- amino acid
- bone marrow
- mesenchymal stem cells
- metabolic syndrome
- signaling pathway
- cell therapy
- smoking cessation
- high throughput sequencing